Literature DB >> 16956440

Efficacy of infliximab in long-lasting refractory Kawasaki disease.

F Zulian, G Zanon, G Martini, G Mescoli, O Milanesi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16956440

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  4 in total

1.  Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.

Authors:  Jane C Burns; Brookie M Best; Asuncion Mejias; Lynn Mahony; David E Fixler; Hasan S Jafri; Marian E Melish; Mary Anne Jackson; Basim I Asmar; David J Lang; James D Connor; Edmund V Capparelli; Monica L Keen; Khalid Mamun; Gregory F Keenan; Octavio Ramilo
Journal:  J Pediatr       Date:  2008-07-30       Impact factor: 4.406

2.  Infliximab treatment for pediatric refractory Kawasaki disease.

Authors:  Laura L Blaisdell; Jennifer A Hayman; Adrian M Moran
Journal:  Pediatr Cardiol       Date:  2011-07-20       Impact factor: 1.655

Review 3.  Recent understanding on diagnosis and management of central nervous system vasculitis in children.

Authors:  Ludovico Iannetti; Roberta Zito; Simone Bruschi; Laura Papetti; Fiorenza Ulgiati; Francesco Nicita; Francesca Del Balzo; Alberto Spalice
Journal:  Clin Dev Immunol       Date:  2012-09-12

4.  Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.

Authors:  Chun-Ling Han; Suo-Lin Zhao
Journal:  Med Sci Monit       Date:  2018-10-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.